U.S. Arthritis Market, Type (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Spondyloarthritis, Juvenile Idiopathic Arthritis (JIA), Others), Product (Treatment and Diagnosis), Drug Type (Branded and Generics), Medication Type (Prescription Drugs and Over-The-Counter Drugs), Route of Administration (Parenteral, Oral, Others), Population Type (Geriatrics, Adults, and Children), End User (Hospital, Specialty Centers, Homecare, Others), Distribution Channel (Direct Tender, Retail Sales, Others) – Industry Trends and Forecast to 2031.
U.S. Arthritis Market Analysis and Size
The major factor that is expected to drive the growth of the U.S. arthritis market is rising patient awareness of arthritis treatment, which leads to increased adoption of diagnosis and treatment. The sedentary lifestyle tradition leading to reduced indulgence in physical activities is also a major factor. There is a substantial rise in obesity and unhealthy food habits which is expected to increase the demand for arthritis drugs. Moreover, the geriatric population is most susceptible to arthritis, which is expected to boost the growth of the market. However, the high cost associated with medication and therapy is expected to hamper the growth of the market.
Data Bridge Market Research analyses that the U.S. arthritis market which was USD 37,910.12 million in 2023, is expected to reach USD 51,145.42 million by 2031, and is expected to undergo a CAGR of 10.20% during the forecast period of 2024 to 2031. “Rheumatoid Arthritis” dominates the type segment of the U.S. arthritis market due to rising prevalence of arthritis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
U.S. Arthritis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Spondyloarthritis, Juvenile Idiopathic Arthritis (JIA), Others), Product (Treatment and Diagnosis), Drug Type (Branded and Generics), Medication Type (Prescription Drugs and Over-The-Counter Drugs), Route of Administration (Parenteral, Oral, Others), Population Type (Geriatrics, Adults, and Children), End User (Hospital, Specialty Centers, Homecare, Others), Distribution Channel (Direct Tender, Retail Sales, Others)
|
|
Market Players Covered
|
GSK plc. (U.K.), Merck & Co., Inc., (U.S.), Pfizer, Inc. (U.S.), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), CSL Limited (Australia), EMERGENT (U.S.), MedImmune, LLC (U.S.), Sanofi (France), Serum Institute of India Pvt. Ltd. (India)
|
|
Market Opportunities
|
|
Market Definition
Arthritis is the swelling and tenderness of one or more joints. The main symptoms of arthritis are joint pain and stiffness, which typically worsen with age. The most common types of arthritis are rheumatoid arthritis and osteoarthritis. Osteoarthritis causes cartilage to break down. Rheumatoid arthritis is a disease in which the immune system attacks the joints, beginning with the lining of the joints.
U.S. Arthritis Market Dynamics
Drivers
- Rise in Patient Awareness of Arthritis
With the increased prevalence and incidence of arthritis worldwide, there is an increase in awareness of the disease. Therefore, rising patient awareness of arthritis is expected to act as a driver for the growth of the arthritis market.
- Increasing Prevalence of Arthritis
Another significant factor influencing the growth rate of the U.S. arthritis market is the increasing prevalence of the disease in the region. Researchers found that more adults in rural areas are affected by arthritis with nearly 1 in 3 affected, than in urban areas in the future decades, the prevalence of doctor-diagnosed arthritis is predicted to rise.
- Surge in Geriatric Population
Osteoarthritis is the most common type of arthritis that affects older people, with rates beginning to rise in their 40s and 50s. The other prevalent complaint among those aged 45 to 64 is joint pain, which leads to visits to the doctor. Multiple kinds of arthritis are frequently identified and classified as various rheumatic illnesses by the age of 65. Hence, the surge in the geriatric population may drive the market growth.
Opportunity
- Strategic Initiatives by Key Players
The increasing prevalence of arthritis gives swelling and tenderness to one or more joints and is often painful so the simultaneous burden of such disease is widely seen among people globally. The dramatic rise in the quality of research and increasing research opportunities is because of various strategic initiatives taken by the key market players in the arthritis market. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market.
Restraints/Challenges
- High Cost of Therapies and Side Effects
However, the high cost of therapies and side effects and complications of various drugs and therapies will impede the growth rate of the U.S. arthritis market. In addition, stringent rules and regulations will further challenge the market in the forecast period mentioned above.
- Storage and Transportation Challenges
Arthritis drugs require stringent storage and transportation conditions, including specific temperature controls to maintain their efficacy. The need for cold chain logistics poses logistical challenges, especially in regions with inadequate infrastructure or limited access to refrigeration facilities. Storage requirements increase operational costs and pose challenges in maintaining drug potency during distribution.
This U.S. arthritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the U.S. arthritis market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa) drug for the treatment of adults with active psoriatic arthritis (PsA), which is a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriatic arthritis. This has helped the company to increase its revenue with this production
U.S. Arthritis Market Scope
The U.S. arthritis market is segmented on the basis of type, product, drug type, medication type, route of administration, population type, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Rheumatoid Arthritis
- Osteoarthritis
- Gout
- Psoriatic Arthritis
- Spondyloarthritis
- Juvenile Idiopathic Arthritis (JIA)
- Others
Product
- Treatment
- Diagnosis
Drug Type
- Branded
- Generics
Medication Type
- Prescription Drugs
- Over-The-Counter Drugs
Route of Administration
- Parenteral
- Oral
- Others
Population Type
- Geriatrics
- Adults
- Children
End User
- Hospitals
- Specialty Centers
- Homecare
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
U.S. Arthritis Market Regional Analysis/Insights
The U.S. arthritis market is analyzed and market size insights and trends are provided by country, type, product, drug type, medication type, route of administration, population type, end user, and distribution channel as referenced above.
U.S. dominates the arthritis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2024 to 2031, due of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The U.S. arthritis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for U.S. arthritis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the U.S. arthritis market. The data is available for historic period 2016-2021.
Competitive Landscape and U.S. Arthritis Market Share Analysis
The U.S. arthritis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to U.S. arthritis market.
Some of the major players operating in the U.S. arthritis market is:
- GSK plc. (U.K.)
- Merck & Co., Inc., (U.S.)
- Pfizer, Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- Johnson & Johnson (U.S.)
- CSL Limited (Australia), EMERGENT (U.S.)
- MedImmune, LLC (U.S.)
- Sanofi (France)
- Serum Institute of India Pvt. Ltd. (India)
SKU-